UroGen Submits NDA for UGN-103 Bladder Cancer Treatment
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
urothelial cancer
Advertisement
UroGen Secures U.S. Patent Protection for ZUSDURI Through 2044
PRINCETON, N.J., July 15, 2026 UroGen Pharma announced that the U.S. Patent and Trademark Office (USPTO) has issued a...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
UroGen Pharma Expands Oncology Capabilities With New Inducement Grants
PRINCETON, N.J., December 5, 2025 — UroGen Pharma Ltd. has announced the issuance of inducement restricted stock units (RSUs)...
Flare and Merck Partner to Advance FX-909 Combo in Cancer
CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...
Advertisement
